GT Biopharma, Inc. Email Format

Biotechnology ResearchCalifornia, United States2-10 Employees

GT Biopharma, Inc. is a biotechnology research company focused on developing cancer immunotherapies. Its work centers on leveraging a proprietary NK cell engager platform to generate novel biopharmaceutical drugs aimed at treating cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and various solid tumors. A key objective is to harness natural killer cells to target tumor cells, with ongoing programs including a B7-H3-targeted approach that has entered early clinical testing. The firm has established a worldwide licensing arrangement with the University of Minnesota to advance and commercialize therapies based on its TriKE technology.

Headquartered in Marina, California, GT Biopharma operates in the clinical-stage segment of the biotechnology industry, pursuing partnerships and regulatory pathways to bring its immuno-oncology therapies forward. The company participates in industry events and maintains a public presence through disclosures and press coverage, reflecting an active development pipeline and ongoing regulatory activity. Recent developments noted include IND submissions for TriKE-based candidates and updates on Phase I testing for its B7-H3-targeted NK cell engager.

Sign up for free to view info

Company overview Employee directory